{"id":"bedaquiline-delamanid-moxifloxacin","safety":{"commonSideEffects":[{"rate":"null","effect":"QT interval prolongation"},{"rate":"null","effect":"Hypotension"},{"rate":"null","effect":"Hypokalemia"}]},"_chembl":{"chemblId":"CHEMBL2105700","moleculeType":"Small molecule","molecularWeight":"671.59"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bedaquiline inhibits the ATP synthase enzyme of Mycobacterium tuberculosis, leading to the disruption of the bacterial energy production and ultimately, cell death.","oneSentence":"Inhibits Mycobacterium tuberculosis ATP synthase","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:54.209Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multidrug-resistant tuberculosis"}]},"trialDetails":[{"nctId":"NCT07170800","phase":"PHASE2","title":"A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets","status":"RECRUITING","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2025-09-19","conditions":"Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":60},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT06114628","phase":"PHASE2","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-01-09","conditions":"Pulmonary Tuberculosis","enrollment":2500},{"nctId":"NCT05766267","phase":"PHASE2, PHASE3","title":"Short-course Regimens for the Treatment of Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2023-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis Infection","enrollment":288},{"nctId":"NCT04550832","phase":"PHASE2","title":"PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)","status":"COMPLETED","sponsor":"LigaChem Biosciences, Inc.","startDate":"2021-10-28","conditions":"Infections and Infestations, Pulmonary Tuberculosis","enrollment":76},{"nctId":"NCT07129629","phase":"PHASE2","title":"Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-08-20","conditions":"Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis","enrollment":45},{"nctId":"NCT07126639","phase":"NA","title":"A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-01","conditions":"Efficacy and Safety","enrollment":200},{"nctId":"NCT06081361","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2023-12-22","conditions":"Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":186},{"nctId":"NCT02754765","phase":"PHASE3","title":"Evaluating Newly Approved Drugs for Multidrug-resistant TB","status":"COMPLETED","sponsor":"Médecins Sans Frontières, France","startDate":"2016-12","conditions":"Tuberculosis, Multidrug-Resistant, Infection, Bacterial, Pulmonary Tuberculoses","enrollment":754},{"nctId":"NCT05926466","phase":"PHASE2","title":"BTZ-043 Dose Evaluation in Combination and Selection","status":"UNKNOWN","sponsor":"Michael Hoelscher","startDate":"2023-09-21","conditions":"Tuberculosis, Pulmonary, Other Specified Pulmonary Tuberculosis","enrollment":90},{"nctId":"NCT03959566","phase":"PHASE2","title":"PanACEA Sutezolid Dose-finding and Combination Evaluation","status":"COMPLETED","sponsor":"Michael Hoelscher","startDate":"2021-05-06","conditions":"Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis","enrollment":75},{"nctId":"NCT03625739","phase":"","title":"Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis","status":"RECRUITING","sponsor":"Beijing Children's Hospital","startDate":"2018-07-01","conditions":"Tuberculosis","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BDM"],"phase":"phase_2","status":"active","brandName":"Bedaquiline, Delamanid, Moxifloxacin","genericName":"Bedaquiline, Delamanid, Moxifloxacin","companyName":"LigaChem Biosciences, Inc.","companyId":"ligachem-biosciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits Mycobacterium tuberculosis ATP synthase Used for Multidrug-resistant tuberculosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}